20 JUNE 2025 6 NEWS ausdoc. com. au
New name for PCOS likely this year
20 JUNE 2025 6 NEWS ausdoc. com. au
‘ There are some very nasty ways to die’
Murder victim Jasmeen Kaur. |
FROM PAGE 5 may lead to accumulated, ongoing and unresolved grief in practitioners” and more research into the extent of PTSD in forensics.
The End
His work has taught him that he cannot shun or ignore death, an attitude he feels is too common in modern society.
But he is aware that curiosity about death and the morbid is a normal part of the human condition, and the proliferation of
|
true-crime entertainment is evidence of that.
He has even co-hosted his own true-crime podcast, Guardians of the Dead.
“ A century ago, there was a lot of death around,” he says.
“ Kids were dying, and families would put the bodies out onto the kitchen table and have a wake to celebrate this person, and friends would visit.
“ There would be a respect for the person, and they would be seen on their way, whereas now
|
|
|
they are just out the door, into the coffin, into the crematorium and that is it.
“ We have sanitised it a lot. I think we really fear it. And I think the more you fear it, the more fearful it becomes.
“ I am not at all worried about death. It is how I get there that worries me because there are some very nasty ways to die.”
It is an attitude Professor Byard brings to his own cases.
Although people are dead by the time they reach him, he sees
|
them as his patients— the same as any doctor.
“ I think it is important to respect and remember these people. They are your patients even though they have gone,” he says.
“ If you do not have compassion with your curiosity, then I think you are missing a lot.”
Professor Byard was awarded an AC in the King’ s Birthday Honours earlier this month.
|
It’ s now even easier to prevent another CV event with Repatha ® * 1, 2
INITIATE NOW ON STREAMLINED AUTHORITY 3
* Repatha ® is indicated for the prevention of CV events( MI, stroke and coronary revascularisation) in adults with established CVD in combination with an optimally dosed statin and / or other lipid-lowering therapies, as an adjunct to diet and exercise. 1‘ Power’: 15 % relative risk reduction with Repatha ® vs placebo in the composite of the primary endpoint beyond optimised statin ± ezetimibe( HR: 0.85; 95 % CI: 0.79 – 0.92, p < 0.001). 2
PBS Information: Authority required( STREAMLINED). Non-familial and familial hypercholesterolaemia. Criteria apply. Refer to PBS Schedule for full authority information.
Refer to full Product Information before prescribing; available from Amgen Australia Pty Ltd, Ph: 1800 803 638 or by scanning the QR code:
For more information on Repatha ® or to report an adverse event or product complaint involving Repatha ®, please contact Amgen Medical Information on 1800 803 638 or visit www. amgenmedinfo. com. au.
Precautions: Hypersensitivity reactions. Concomitant lipid-lowering therapies – check all relevant prescribing information. Immunogenic potential. Pregnancy Category: B1. Caution – breastfeeding. Adverse Reactions: Common – nasopharyngitis, upper respiratory tract infection, influenza, back pain, arthralgia, nausea, rash, and injection site reactions( including injection site pain, erythema, bruising, swelling or haemorrhage).
Abbreviations: CI, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; PBS, Pharmaceutical Benefits Scheme.
References: 1. Repatha ®( evolocumab) Approved Product Information. 2. Sabatine MS, et al. N Engl J Med. 2017; 376( 18): 1713 – 1722. 3. Pharmaceutical Benefits Scheme. Evolocumab. Available at: https:// www. pbs. gov. au / medicine / item / 10958R [ Accessed June 2024 ].
* 1,2
Visit repatha. com. au
for patient resources and information on how to prescribe Repatha ® on the PBS or privately
New name for PCOS likely this year
Jamie Thannoo PCOS will probably have a new name before 2025 is over, a leading endocrinologist says.
More than 85 % of patients and 76 % of doctors want a new name for the condition, according to survey results from 7700 people, published in eClinicalMedicine.
“ There is a long history to this idea,” said endocrinologist and lead author Professor Helena Teede, who suggested one option could be to call the condition‘ metabolic endocrine reproductive syndrome’.
“ When this condition was originally described, it was discovered through surgical exploration of the ovaries, which found what appeared to be cysts on the ovaries.
“ We have moved on a long way since then, and we now know it is a hormonal endocrine condition.”
Not all patients had ovarian‘ cysts’, which were technically not cysts but immature ovarian follicles, and other impacts included possible insulin resistance, type 2 diabetes, hypertension, cardiovascular disease, sleep apnoea, infertility, acne, depression and anxiety.
Professor Teede said a name would probably be agreed later this year.
Other suggestions for a name were‘ hyperandrogenic anovulation’ or‘ hyperandrogenic persistent ovulatory dysfunction syndrome’.
eClinicalMedicine 2025; 28 May.
Amgen Australia Pty Ltd. ABN 31 051 057 428, Sydney NSW 2000. © 2024 Amgen Inc. All rights reserved. AUS-145-0624-80014. AMG4138. Date of preparation: June 2024.
Professor Helena Teede.
AMG4138 _ Repatha _ Streamlined Authority _ AusDoc _ A4 _ 210x273mmH _ OctNov _ R0.2 _ FA. indd 1 26 / 8 / 2024 6:17 PM